Abstract
Malaria infections in pregnancy are associated with adverse outcomes for both mother and child. There are few data on hyper-reactive malarial splenomegaly, an aberrant immunological response to chronic or recurrent malaria in pregnancy. This retrospective assessment reviewed the impact of mefloquine treatment on pregnant women with suspected hyper-reactive malarial splenomegaly in an area of low malaria transmission in the 1990s, showing significant reductions in spleen size and anemia and anti-malarial antibody titers without any notable negative effect on treated women or their newborns.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Protozoan / immunology
-
Antimalarials / therapeutic use*
-
Female
-
Humans
-
Hypersplenism / drug therapy
-
Hypersplenism / etiology
-
Hypersplenism / immunology
-
Immunoglobulin M / immunology
-
Malaria / complications
-
Malaria / drug therapy*
-
Malaria / immunology
-
Mefloquine / therapeutic use*
-
Plasmodium / immunology
-
Pregnancy
-
Pregnancy Complications, Parasitic / drug therapy*
-
Pregnancy Complications, Parasitic / immunology
-
Retrospective Studies
-
Splenomegaly / drug therapy*
-
Splenomegaly / etiology
-
Splenomegaly / immunology
Substances
-
Antibodies, Protozoan
-
Antimalarials
-
Immunoglobulin M
-
Mefloquine